Moderna (MRNA) Stock Forecast & Predictions for 2025, 2026, 2027–2030 and Beyond

Moderna is an American pharmaceutical company that focuses on developing medicines based on messenger ribonucleic acid (mRNA). It is best known for creating the Moderna COVID-19 vaccine.

MRNA stock price forecasts are based on a thorough analysis of current market trends and the company’s financial performance. A comprehensive assessment provides insight into the future performance of MRNA stock quotes. Currently, analysts predict a decline in the stock price, with estimates varying. 

This article examines expert forecasts of MRNA rates for the years ahead and considers all factors that can influence the asset’s price.

The article covers the following subjects:

Major Takeaways

• The current price of #MRNA is $33.86 as of 26.03.2025.
• The MRNA price reached its all-time high of $484.47 on 2021-08-09. The stock’s all-time low of $12.26 was recorded on 2019-08-05.
• LongForecast expects MRNA to trade in the range of $21.95–$38.10 in 2025, while CoinPriceForecast predicts that the price will reach $38.15 by the end of the year.
• Markettalkz forecasts the stock to surge to $110.53 in 2026 due to new drug developments, while LongForecast expects a decline to $49.08.
• Forecasts for 2027–2028 diverge: Markettalkz anticipates an increase above $140, while LongForecast expects a drop to $9.98. 
• According to CoinPriceForecast, the price may reach $87.43 by 2030, whereas Stockscan foresees a jump to $459.45.
• Since the pandemic, interest in vaccines has diminished, leading to a drop in MRNA’s stock price since 2021.
• The MRNA price movement will depend on the results of clinical trials, financial reports, government orders, and analyst ratings.

MRNA Real-Time Market Status

The #MRNA stock is trading at $33.86 as of 26.03.2025.

When analyzing the Moderna stock, it is essential to monitor key indicators such as market capitalization, price movement, the number of shares outstanding, and the P/E ratio. These indicators help assess the company’s scale, attractiveness to investors, and MRNA‘s rate changes over the long term.

Indicator	Value
Market cap	$13.15 billion
All-time high	$484.47
All-time low	$12.26
Shares outstanding	386.6 million
Dividend yield	The company does not pay dividends
P/E ratio	−3.5x

MRNA Stock Price Forecast for 2025 Based on Technical Analysis

Moderna (MRNA) shares continue to trade in a descending channel. The EMA and SMA (around 34.9) are showing bearish divergence, confirming the downtrend. The RSI is standing at 34.79 near the oversold zone, suggesting that bearish momentum is weakening. The MACD indicator is forming a bullish divergence: the histogram is green, and the lines are converging, signaling that the decline is decelerating.

Bollinger bands have narrowed, indicating a decrease in volatility and a potential exit from consolidation soon. Trading volumes remain modest, confirming the uncertainty among market participants. Although a weak downward momentum persists, technical indicators point to a possible reversal.

The table below provides MRNA’s price forecast until the end of 2025.

Month	Minimum, $	Maximum, $
April	29.85	37.5
May	31.2	382
June	32	39.5
July	33.1	40
August	34.5	42.3
September	35.8	44.2
October	36.2	45.1
November	37.4	46.8
December	38	48

Long-Term Trading Plan for Moderna Inc. (#MRNA) for 2025

The long-term trading plan for #MRNA in 2025 is based on the ongoing downtrend, where the price is moving in the 29–45 channel. The key support remains at 30. If the price breaks through and settles above 37, one may consider medium-term long trades with the target near 45–50.

An alternative scenario suggests that the asset may test the support of 30 and rebound. The RSI is near the oversold zone, and the MACD indicator signals a potential reversal. At the same time, volatility is decreasing. It is crucial to track trading volumes since the volume growth during bullish candlesticks will confirm buyer interest. A stop-loss order can be placed at 29.50. Conservative traders should wait until the price breaks through the boundary of the descending channel. Aggressive traders can look for an entry point near the support. However, it is essential to follow the rules of risk management.

Analysts’ MRNA Shares Price Projections for 2025

Investors are closely watching the prospects of Moderna. Following the surge during COVID-19, the company’s stock has experienced significant fluctuations. Analysts make varying predictions for MRNA’s performance in 2025, ranging from moderate growth to a possible correction.

Markettalkz

Price range: $81.36–$125.04 (as of 23.03.2025).

Markettalkz forecasts that Moderna’s average share price will be $96.95 in 2025. Analysts are counting on steady demand for the company’s drugs, expanding research in mRNA vaccines, and the overall stability of the biotechnology sector.

Year	Minimum, $	Average, $	Maximum, $
2025	81.36	96.95	125.04

LongForecast

Price range: $21.20–$38.10 (as of 23.03.2025).

LongForecast, in contrast, expects a noticeable price slump. The stock may fall to $23.04 by July and recover to $27.66 by December. Analysts attribute this scenario to a possible revenue decrease and strong competition in the industry.

Month	Open, $	Min–Max, $	Close, $
March	30.96	28.27–38.10	31.1
April	31.1	25.93–34.89	29.61
May	29.61	23.16–29.61	25.17
June	25.17	21.95–25.77	23.86
July	23.86	21.20–24.88	23.04
August	23.04	21.99–25.81	23.9
September	23.9	22.79–26.75	24.77
October	24.77	23.64–27.76	25.7
November	25.7	24.53–28.79	26.66
December	26.66	25.45–29.87	27.66

CoinPriceForecast

Price range: $36.60–$38.15 (as of 23.03.2025).

CoinPriceForecast anticipates the stock price to advance to $38.15 by the end of 2025. The optimistic outlook is driven by the company’s research in new areas and the extension of strategic partnerships.

Year	Mid-Year, $	Year-End, $
2025	36.60	38.15

Analysts’ MRNA Shares Price Projections for 2026

2026 may mark a pivotal year for the company, fueled by breakthroughs in immunotherapy research and the accelerating integration of AI in drug development.

Markettalkz

Price range: $92.75–$143.69 (as of 23.03.2025).

Markettalkz predicts that Moderna shares will reach an average price of $110.53, buoyed by advances in the treatment of autoimmune diseases and cancer, as well as the integration of AI technologies into pharmaceutical production.

Year	Minimum, $	Average, $	Maximum, $
2026	92.75	110.53	143.69

LongForecast

Price range: $27.66–$46.84 (as of 23.03.2025).

According to LongForecast, the MRNA price may reach a high of $46.84 in June 2026 before retreating to $31.04 by December. This projection underscores the sector’s inherent volatility and its sensitivity to medical research and industry news.

Month	Open, $	Min–Max, $	Close, $
January	27.66	27.66–34.35	31.81
June	37.71	37.71–46.84	43.37
December	32.83	28.56–33.52	31.04

CoinPriceForecast

Price range: $44.38–$50.98 (as of 23.03.2025).

CoinPriceForecast expects moderate appreciation. In December, the MRNA exchange rate is expected to trade at $50.98. The forecast is based on the prospects of Moderna’s new drug developments, especially in immunotherapy.

Year	Mid-Year, $	Year-End, $
2026	44.38	50.98

Analysts’ MRNA Shares Price Projections for 2027

Expert estimates of the MRNA exchange rate in 2027 vary considerably. Some forecasts point to steady upward movement, while others suggest a slump.

Markettalkz

Price range: $106.66–$165.24 (as of 23.03.2025).

Markettalkz expects MRNA to climb firmly to an average price of $127.11, spurred by the company’s expansion and partnerships, including those in the treatment of malaria and tuberculosis. This approach will strengthen Moderna’s position in mRNA therapeutics.

Year	Minimum, $	Average, $	Maximum, $
2027	106.66	127.11	165.24

LongForecast

Price range: $10.80–$32.29 (as of 23.03.2025).

LongForecast, on the contrary, indicates a strong depreciation of the MRNA price. At the beginning of the year, the asset will trade around $29.90. However, by December, the price may plummet to $11.74. This pessimistic scenario takes into account potential market and corporate risks.

Month	Open, $	Min–Max, $	Close, $
January	31.04	27.51–32.29	29.90
June	28.74	22.48–28.74	24.43
December	13.8	10.80–13.80	11.74

CoinPriceForecast

Price range: $55.66–$64.01 (as of 23.03.2025).

CoinPriceForecast predicts a more sustainable increase, with the price reaching $64.01 by the end of the year. This is due to the long-term belief in the mRNA vaccine and the prospects of Moderna’s product line expansion.

Year	Mid-Year, $	Year-End, $
2027	55.66	64.01

Analysts’ MRNA Shares Price Projections for 2028

Forecasts for 2028 show a wide range of estimates, reflecting uncertainty about Moderna’s future success. Analysts take into account both breakthrough research and possible market risks.

Markettalkz

Price range: $120.53–$186.72 (as of 23.03.2025).

Markettalkz expects MRNA to skyrocket to $186.72, bolstered by innovations in cardiovascular disease treatment and the development of mRNA therapeutics for regenerative medicine. The VEGF-A program is already showing good results, which strengthens investors’ confidence in the company.

Year	Minimum, $	Average, $	Maximum, $
2028	120.53	143.63	186.72

LongForecast

Price range: $9.18–$13.89 (as of 23.03.2025).

LongForecast believes the stock will trade in the range of $9.18–$13.89. The forecast indicates moderate volatility and limited upside prospects in the short term due to intense competition in the biotechnology sector and a slowdown in the development of Moderna’s individual businesses.

Month	Open, $	Min–Max, $	Close, $
January	11.74	9.18–11.74	9.98
June	12.92	11.83–13.89	12.86
December	11.94	10.30–12.10	11.20

CoinPriceForecast

Price range: $65.42–$72.78 (as of 23.03.2025).

CoinPriceForecast holds a cautiously optimistic view regarding MRNA’s future. The price is expected to climb to $72.78 by the end of 2028, supported by Moderna’s growing market presence, the sustainable development of mRNA-based products, and the expansion of the clinical trials portfolio.

Year	Mid-Year, $	Year-End, $
2028	65.42	72.78

Analysts’ MRNA Shares Price Projections for 2029

Moderna can significantly strengthen its position in 2029 by successfully implementing long-term research programs.

Markettalkz

Price range: $137.40–$212.86 (as of 23.03.2025).

Markettalkz expects the MRNA rate to gain traction thanks to new product launches and achievements in clinical trials. Special attention will be paid to mRNA technologies in gene therapy. The company is actively collaborating with universities to develop CRISPR solutions for treating inherited diseases.

Year	Minimum, $	Average, $	Maximum, $
2029	137.40	163.74	212.86

Stockscan

Price range: $196.3–$504.6 (as of 23.03.2025).

Stockscan offers a highly inconsistent forecast. The price may reach $468.6 at the beginning of the year, dip to $445.2 in the middle, and range from $196.3 to $504.6 in December. Such a spread indicates considerable uncertainty and dependence on Moderna’s success in key projects.

Month	Minimum, $	Average, $	Maximum, $
January	456.1	460.8	468.6
June	429.4	444.8	445.2
December	196.3	198.2	504.6

CoinPriceForecast

Price range: $80.06–$83.01 (as of 23.03.2025).

Analysts at CoinPriceForecast are also upbeat, predicting that the share price may soar to $83.01 by the end of 2029. Experts note that this appreciation will be linked to advancements in treating rare diseases.

Year	Mid-Year, $	Year-End, $
2029	80.06	83.01

Analysts’ MRNA Shares Price Projections for 2030

The start of the new decade may mark a period of significant momentum for Moderna, as the company focuses on personalized medicine, digital health technologies, and gene therapy. Many analysts believe that innovations in biotechnology will be the key catalyst for MRNA’s future performance.

Markettalkz

Price range: $158.01–$244.79 (as of 23.03.2025).

Markettalkz forecasts MRNA to edge up, driven by advances in mRNA product development and a stronger position in personalized medicine. The price may surge to $244.79. Moderna is investing in digital platforms to improve treatment accuracy, positively impacting the company’s stock price.

Year	Minimum, $	Average, $	Maximum, $
2030	158.01	188.30	244.79

Stockscan

Price range: $197.3–$317.1 (as of 23.03.2025).

Stockscan anticipates consistent gains. The stock may reach $317.1 by the end of the year, marking the most optimistic estimate.

Month	Minimum, $	Average, $	Maximum, $
January	197.3	199.5	202.7
June	235.7	244.5	244.6
December	297.5	316.3	317.1

CoinPriceForecast

Price range: $86.71–$87.43 (as of 23.03.2025).

CoinPriceForecast predicts a more subdued increase, with the price rising to $87.43 by the end of the year. Analysts believe MRNA can be a good long-term investment amid progress in chronic disease treatment.

Year	Mid-Year, $	Year-End, $
2030	86.71	87.43

Analysts’ MRNA Shares Price Projections until 2050

According to long-term projections, Moderna’s stock is poised to rise in value. Markettalkz suggests that the average price may climb to $188.30 by 2030, to $349.92 in 2035, and skyrocket to an impressive $3,100 by 2050. This forecast reflects confidence in the company’s prospects in mRNA technologies, gene therapy, and personalized medicine.

Stockscan also anticipates an uptrend, with the asset reaching $202.70 in 2030, $804.20 in 2035, $1,116 in 2040, and $1,474 by 2050. These estimates are grounded in Moderna’s earnings data and the upside potential of its research programs. Besides, this increase may be fueled by advances in new therapeutic areas, including cardiology and oncology.

Year	Markettalkz, $	Stockscan, $
2030	188.3	202.7
2035	349.92	804.2
2040	656.06	1,116
2050	3,100	1,474

Overall, the forecasts until 2050 assume significant gains for MRNA. However, such long-term projections remain highly conditional, hinging on the company’s progress in biotechnology, the outcomes of clinical trials, and broader industry trends.

Market Sentiment for MRNA (Moderna) on Social Media

Media sentiment plays a crucial role in shaping investor expectations. Social networks serve as a platform for sharing opinions and predictions, often swaying short-term price movements. Regarding Moderna (#MRNA) shares, mixed sentiment is observed.

Analyst @Han_Akamatsu anticipates that the quotes may increase after hitting the support of $33–$34 and expects a breakout above $37. Moreover, the author of the post points to the formation of a Falling Wedge bullish pattern.

At the same time, @Ben_Brunier mentions a divergence in the RSI indicator. Besides, the user notes that the company’s CEO has repurchased MRNA shares worth $9 million, which is also a positive signal.

In general, the current market sentiment surrounding MRNA is moderately optimistic, with cautious expectations of stock price upsurge and interest from institutional investors.

#MRNA Price History

Moderna reached its all-time high of $484.47 on 2021-08-09. The lowest price of MRNA was recorded on 2019-08-05 when the stock declined to $12.26.

It is crucial to evaluate historical data to make our forecasts as accurate as possible. The chart below shows the #MRNA price performance over the last ten years.

Between January 2019 and December 2022, the Moderna stock exhibited high volatility and robust growth, mirroring the dynamic evolution of the biotechnology sector. The stock price began the year at $16.60 and saw a steady increase, reaching $20.35 by March 2019.

The pivotal moment occurred in 2020 amidst a global health crisis. Moderna’s contributions to the development of a coronavirus vaccine drove the stock price from $25.93 in February 2020 to a high of $173.16 in January 2021, showcasing an unparalleled surge. However, the peak was followed by fluctuations, with the stock price reaching a high of $497.49 in July 2021. After that, the stock began to slide, reaching a low of $179.62 in December 2022.

In 2023, MRNA’s stock price experienced a significant decline from $204.1 in January to a low of $65.27 in November. Nevertheless, the price has been on a gradual upward trajectory, reflecting a sustainable bullish trend.

However, this upward movement proved to be short-lived. Once the pandemic ended, demand for vaccines dropped, negatively impacting the company’s financial performance. In January 2025, Moderna downgraded its earnings forecast, causing MRNA to fall by 21.4%.

MRNA Shares Fundamental Analysis

Fundamental analysis involves evaluating a company’s performance based on its financial and operational metrics. In this section, we examine the key factors influencing Moderna’s share price, including economic conditions, technological innovation, and regulatory risks.

What Factors Affect the #MRNA Stock?

The MRNA share price movement depends on a variety of fundamental factors:

• Patents relating to mRNA technology. The COVID-19 pandemic challenged pharmaceutical companies, pushing their stocks higher with the development of coronavirus vaccines, but now the price is slowly declining.
• Regulatory changes. The regulatory landscape for healthcare companies can both increase and decrease research and manufacturing costs.
• Macroeconomic conditions. Inflation, interest rates, and geopolitical events affect MRNA stocks. During periods of economic uncertainty, investors often shift their priorities and turn to safe-haven assets to preserve their capital. Against this backdrop, stocks may see wide fluctuations.
• Consumer spending. In the absence of global risks of emerging infectious diseases, the development of new vaccines is greatly diminished. As a result, investors are reluctant to invest in expensive research.

More Facts About Moderna Inc. (#MRNA)

Moderna, Inc. is one of the largest biotechnology companies in the United States, specializing in the development of messenger RNA-based drugs. The company was founded in 2010.

During the COVID-19 pandemic, Moderna, Inc. was developing a coronavirus vaccine, which caused its stock price to rise significantly. In addition, MRNA was included in the S&P 500 Index on July 21, 2021, replacing the pharmaceutical company Alexion Pharmaceuticals. These two factors attracted investors to Moderna, Inc., but it was a short-lived interest.

Advantages and Disadvantages of Investing in #MRNA

Investing in MRNA shares has its advantages and disadvantages, which are important to consider when making decisions.

Advantages

• Moderna is actively developing mRNA-based vaccines for cancer and cardiovascular disease treatment.
• The company is included in the S&P 500 index, reflecting its market significance and institutional investor confidence.
• Moderna has strong strategic partnerships, including collaborations with UNICEF and governments in low-income countries.
• The company invests in AI technologies to accelerate drug discovery and development.
• Moderna has expertise in large-scale production and distribution of biologics.

Disadvantages

• Lower demand for drugs may weaken financial performance and put pressure on MRNA’s value.
• Intense competition in the biotechnology sector, with strong players like Pfizer and BioNTech potentially limiting market share.
• High risk of clinical trial failures.
• The lack of a diverse portfolio of commercially successful products increases business vulnerability.
• The stock remains highly volatile and prone to sharp swings, even in response to relatively minor news.

Remember that investing in the biotechnology sector always involves a high degree of uncertainty. Despite Moderna’s scientific potential, the stock remains volatile. Therefore, investors should weigh all risks before making decisions.

How We Make Forecasts

We employ a comprehensive methodology to build forecasts:

• Short-term forecasts are based on market data. Technical analysis and indicators help to identify the current trend on lower time frames.
• Medium-term forecasts rely on fundamental analysis involving the assessment of earnings, the debt-to-equity ratio, dividends, reputation, innovative technologies, etc.
• Long-term forecasts take into account behavioral patterns specific to the industry, broader market trends, the company’s position within its sector, and projections from independent analysts.

In order to make an accurate and comprehensive forecast, we consider both internal factors affecting the price of an asset and external factors.

Conclusion: Is MRNA a Good Investment?

Moderna remains a highly ambitious biotech company, exploring innovative concepts in mRNA therapeutics, particularly aimed at treating cancer and heart disease. Even in the face of recent market challenges, the company is committed to fostering innovation and broadening its product line. 

#MRNA can be an appealing asset for long-term investors, especially if the portfolio is thoroughly diversified. However, high volatility, dependence on clinical trial results, and increased competition make investments moderately risky and require a balanced approach.

Moderna Inc. (#MRNA) Price Prediction FAQ’s

What is the current price of the Moderna (#MRNA) stock?

The current MRNA stock price is $33.86 as of 26.03.2025.

What is Moderna’s stock price outlook?

Analysts’ opinions diverge: some expect a recovery after a challenging 2024, while others believe that the downward trend may continue until 2026. Long-term forecasts are positive, especially taking into account the development of mRNA technologies and oncology treatment.

What is Moderna’s stock price outlook for 2025?

LongForecast predicts that the MRNA price will range between $21.20 and $38.15. CoinPriceForecast expects a moderate uptick to $38.15. According to Markettalkz, the share price may surge to $125.04. Such positive forecasts are based on reviving investor interest in the biotechnology sector.

What is Moderna’s price forecast over the next 12 months?

Analysts believe the MRNA stock will range between $22 and $40. Besides, the price may climb even higher if clinical trials are successful. Stable growth is expected closer to the end of 2025, provided there are positive fundamental factors.

What factors affect the valuation of Moderna’s stock in 2025?

Key factors include progress in clinical trials, new partnership agreements, research funding, the rate of new drug distribution, and the overall state of the biotechnology sector and the global economy.

How much will shares of Moderna be worth in 2030?

According to CoinPriceForecast and Markettalkz, the price may reach $87–$244 by 2030. Stockscan presents a more optimistic scenario, suggesting the MRNA rate will soar to $317. The realization of these estimates depends on advances in gene therapy and cancer treatment.

Price chart of MRNA in real time mode

The content of this article reflects the author’s opinion and does not necessarily reflect the official position of LiteFinance broker. The material published on this page is provided for informational purposes only and should not be considered as the provision of investment advice for the purposes of Directive 2014/65/EU.

According to copyright law, this article is considered intellectual property, which includes a prohibition on copying and distributing it without consent.